Tucidinostat Plus Apatinib for Advanced Osteosarcoma
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This phase II study was designed to assess the efficacy and safety of the combination of
Apatinib, Tucidinostat (chidamide), a histone deacetylase inhibitor in relapsed or refractory
osteosarcoma patients.